1	State of Arkansas
2	81st General Assembly
3	Regular Session, 1997 S.C.R. 8
4	By: Senate Public Health Committee
5	
6	
7	SENATE CONCURRENT RESOLUTION
8	URGING THE CONGRESS OF THE UNITED STATES TO AMEND THE
9	FEDERAL FOOD, DRUG, AND COSMETIC ACT AND THE PUBLIC HEALTH
10	SERVICE ACT TO FACILITATE THE DEVELOPMENT AND APPROVAL OF
11	NEW DRUGS AND BIOLOGICS.
12	
13	Subtitle
14	URGING CONGRESS TO AMEND THE FEDERAL
15	FOOD, DRUG, AND COSMETIC ACT AND PUBLIC
16	HEALTH SERVICE ACT FOR DEVELOPMENT AND
17	APPROVAL OF NEW DRUGS AND BIOLOGICS.
18	
19	WHEREAS, improving patient access to quality health care is a paramount
20	national goal; and
21	WHEREAS, the key to improved health care, especially for persons with
22	serious unmet medical needs, is the rapid approval of safe and effective new
23	drugs, biological products, and medical devices; and
24	WHEREAS, minimizing the delay between discovery and eventual approval of
25	a new drug, biological product, or medical device derived from research
26	conducted by innovative pharmaceutical and biotechnology companies could
27	improve the lives of millions of Americans; and
28	WHEREAS, current limitations on the dissemination of information about
29	pharmaceutical products reduce the availability of information to physicians,
30	other health care professionals, and patients, and unfairly limit the right of
31	free speech guaranteed by the First Amendment to the United States
32	Constitution; and
33	WHEREAS, the current rules and practices governing the review of new
34	drugs, biological products, and medical devices by the United States Food and
35	Drug Administration can delay approvals and are unnecessarily expensive;

36

2 NOW THEREFORE, 3 BE IT RESOLVED BY THE SENATE OF THE EIGHTY-FIRST GENERAL ASSEMBLY OF THE STATE 4 OF ARKANSAS, THE HOUSE OF REPRESENTATIVES CONCURRING THEREIN: That we respectfully urge the Congress of the United States to address 6 this important issue by enacting comprehensive legislation to facilitate the 7 rapid review and approval of innovative new drugs, biological products, and 8 medical devices, without compromising patient safety or product effectiveness. BE IT FURTHER RESOLVED that copies of this resolution be transmitted 10 forthwith to the President of the United States, the Speaker of the United 11 States House of Representatives, the President of the United States Senate, 12 and to each member of the Arkansas Congressional Delegation.

1